Tobradex Dosing
For bacterial conjunctivitis or blepharokeratoconjunctivitis, instill 1-2 drops of Tobradex (tobramycin 0.3%/dexamethasone 0.1%) into the affected eye(s) every 4-6 hours initially, then taper based on clinical response. 1
Standard Dosing Regimen
Acute Phase (First 24-48 hours)
- Instill 1-2 drops every 2 hours while awake for severe inflammation or bacterial keratitis
- This intensive initial dosing delivers approximately 2.4 mg of dexamethasone daily if given in both eyes 1
Maintenance Phase (After 48 hours)
- Reduce to 1-2 drops every 4-6 hours (four times daily)
- Continue for 7-21 days depending on severity and clinical response 2
- Daily dexamethasone dose at this frequency is approximately 1.2 mg 1
Tapering
- Gradually reduce frequency as inflammation resolves
- Treatment duration should be guided by severity of blepharitis/conjunctivitis and response to therapy 3
Clinical Context
The combination of tobramycin (antibiotic) and dexamethasone (corticosteroid) provides both antimicrobial coverage and anti-inflammatory effects. Tobradex has demonstrated superior efficacy compared to antibiotic alone in controlling post-surgical inflammation 2, with 51% of patients achieving complete resolution of anterior chamber inflammation by day 8 versus only 21% with tobramycin alone.
Specific Indications from Guidelines
For blepharitis/blepharokeratoconjunctivitis: The 2024 Blepharitis Preferred Practice Pattern notes that tobramycin/dexamethasone suspension has been evaluated in manufacturer-sponsored studies and appears to reduce signs and symptoms of blepharitis, though this is considered off-label use 3. The frequency and duration should be adjusted based on severity.
For bacterial conjunctivitis: While not first-line for mild cases, Tobradex can be used for moderate-to-severe bacterial conjunctivitis with significant inflammation 4.
Important Safety Considerations
Monitor for Steroid-Related Complications
- Check intraocular pressure (IOP) regularly during treatment, especially beyond 2 weeks
- Dexamethasone carries higher risk of IOP elevation compared to loteprednol 5: 7.48% of patients experienced IOP increases ≥10 mmHg with dexamethasone/tobramycin versus 1.95% with loteprednol/tobramycin after 28 days
- Risk of cataract progression with prolonged use 3
Storage and Handling
- Refrigerate and shake well before instillation 6, 7
- Contains benzalkonium chloride 0.01% as preservative 1
Contraindications
- Avoid in viral or fungal ocular infections
- Use caution in patients with glaucoma or steroid responders
- Not recommended for prolonged use (>8 weeks) without ophthalmology supervision 8
Comparative Efficacy
Research demonstrates that tobramycin/dexamethasone provides faster resolution of inflammation compared to tobramycin/loteprednol 9, with significantly lower total ocular inflammation scores (1.8 vs 3.4, P=0.002) at 3-5 days post-treatment in blepharokeratoconjunctivitis patients. However, this comes at the cost of higher IOP risk with dexamethasone.
For post-cataract surgery prophylaxis, the standard regimen is four times daily starting the day before surgery through day 21, which has shown 97.4% clinical effectiveness 10.